Journal
BONE MARROW TRANSPLANTATION
Volume 47, Issue 7, Pages 946-951Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2011.208
Keywords
multiple sclerosis; TBI; CY; hematopoietic cell transplantation; oligoclonal bands
Categories
Funding
- National Institute of Allergy and Infectious Diseases [N01AI05419-16-0-1, N01-AI-05408]
- National Heart, Lung and Blood Institute [P01HL036444]
- National Cancer Institute, National Institutes of Health, Department of Health and Human Services [P30CA015704]
- US Department of Education's National Institute on Disability and Rehabilitation Research [H133B980017]
Ask authors/readers for more resources
The purpose of the study was to determine the long-term safety and effectiveness of high-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT) in advanced multiple sclerosis (MS). TBI, CY and antithymocyte globulin were followed by transplantation of autologous, CD34-selected PBSCs. Neurological examinations, brain magnetic resonance imaging and cerebrospinal fluid (CSF) for oligoclonal bands (OCB) were serially evaluated. Patients (n = 26, mean Expanded Disability Status Scale (EDSS) = 7.0, 17 secondary progressive, 8 primary progressive, 1 relapsing/remitting) were followed for a median of 48 months after HDIT followed by AHCT. The 72-month probability of worsening >= 1.0 EDSS point was 0.52 (95% confidence interval, 0.30-0.75). Five patients had an EDSS at baseline of <= 6.0; four of them had not failed treatment at last study visit. OCB in CSF persisted with minor changes in the banding pattern. Four new or enhancing lesions were seen on MRI, all within 13 months of treatment. In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable for as long as 7 years after transplant. Non-inflammatory events may have contributed to neurological worsening after treatment. HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available